Literature DB >> 30654042

Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system.

Mohammed S O Tagod1, Satoshi Mizuta2, Yuki Sakai2, Masashi Iwasaki3, Kengo Shiraishi2, Hiroaki Senju4, Hiroshi Mukae5, Craig T Morita6, Yoshimasa Tanaka7.   

Abstract

The adoptive transfer of immune effector cells, such as CD8+ killer αβ T cells, γδ T cells, NK (natural killer) cells, and genetically-modified T cells, has been receiving increasing attention. It is essential to determine cellular cytotoxicity so as to monitor the function and quality of ex vivo-expanded immune effector cells before infusion. The most common method is the [51Cr]-sodium chromate release assay. It is, however, preferable to avoid the use of radioactive materials in clinical laboratories. In order to establish a non-radioactive alternative to the standard radioactive assay, we previously synthesized a chelate-forming prodrug (BM-HT) and demonstrated that a combination of BM-HT and europium (Eu3+) was useful to determine NK cell-mediated cytotoxicity. In the present study, we examined whether or not this improved assay system could be used to determine the cellular cytotoxicity exhibited by Vγ2Vδ2+ γδ T cells. In addition, we compared Eu3+ and terbium (Tb3+) in the measurement of cellular cytotoxicity. Our assay system using BM-HT could be used successfully for the analysis of both γδ T cell receptor (TCR)- and CD16-mediated cytotoxicity. When the intensity of fluorescence was compared between Eu3+ and Tb3+, Tb3+ chelate was more sensitive than Eu3+ chelate, suggesting that the detection system using Tb3+ is superior to Eu3+ when tumor cells are not efficiently labeled with BM-HT. The method established herein is expected to promote the development of novel adoptive cell therapies for cancer.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Europium; Nitrogen-containing bisphosphonate; Non-radioactive cellular cytotoxicity assay; Terbium; Terpyridine; γδ T cells

Mesh:

Substances:

Year:  2019        PMID: 30654042      PMCID: PMC6817948          DOI: 10.1016/j.jim.2019.01.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  37 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

3.  Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells.

Authors:  Hong Wang; Olivier Henry; Mark D Distefano; Yen-Chih Wang; Johanna Räikkönen; Jukka Mönkkönen; Yoshimasa Tanaka; Craig T Morita
Journal:  J Immunol       Date:  2013-07-05       Impact factor: 5.422

4.  Studies on the nonmevalonate terpene biosynthetic pathway: metabolic role of IspH (LytB) protein.

Authors:  Felix Rohdich; Stefan Hecht; Katrin Gärtner; Petra Adam; Cornelia Krieger; Sabine Amslinger; Duilio Arigoni; Adelbert Bacher; Wolfgang Eisenreich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 5.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

6.  Modified procedure for labelling target cells in a europium release assay of natural killer cell activity.

Authors:  R Pacifici; S Di Carlo; A Bacosi; I Altieri; S Pichini; P Zuccaro
Journal:  J Immunol Methods       Date:  1993-05-05       Impact factor: 2.303

7.  Nonpeptide ligands for human gamma delta T cells.

Authors:  Y Tanaka; S Sano; E Nieves; G De Libero; D Rosa; R L Modlin; M B Brenner; B R Bloom; C T Morita
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

9.  Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands.

Authors:  P Constant; F Davodeau; M A Peyrat; Y Poquet; G Puzo; M Bonneville; J J Fournié
Journal:  Science       Date:  1994-04-08       Impact factor: 47.728

10.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

View more
  2 in total

1.  A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.

Authors:  Jin Li; Nicholas A Lentini; David F Wiemer; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2019-10-16       Impact factor: 5.858

2.  Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.

Authors:  Wei Zhang; Qi Yin; Haidong Huang; Jingjing Lu; Hao Qin; Si Chen; Wenjun Zhang; Xiaoping Su; Weihong Sun; Yuchao Dong; Qiang Li
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.